PolyCYPs: optimising a preclinical platform tool to reduce pharmaceutical attrition rates

The major healthcare imperatives are to deliver effective prevention and treatment of diseases. Whist pharmaceutical intervention in disease progress is effective in many cases, the use of medicines can also lead to adverse reactions resulting in the need for further medical intervention, compounding the cost of therapy. The aim of this project is to further develop a platform product for which the technical feasibility has been successfully achieved. The outcome will be a platform technology, which as well as increasing revenues and employment at a UK SME with mainly overseas clients, will allow the greater exploration of the chemical space of a potential drug to overcome the main cause of adverse reactions, polymorphic variation of cytochrome P450 enzymes (CYPs). This will allow greater assessment of drug metabolite safety, enabling Pharma clients to innovatively deliver improved medicines with more predictable properties and will further enable greener routes to the production of complex pharmaceuticals and other chemicals that consume fewer resources and produce less waste.